Real‐World Data on Prognostic Factors for Overall Survival in EGFR Mutation‐Positive Advanced Non‐Small Cell Lung Cancer Patients Treated with First‐Line Gefitinib

Documenti analoghi

• Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors
  di: Lee, Jih‐Hsiang, et al.
  Pubblicazione: (2019)
• Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
  di: Gow, Chien-Hung, et al.
  Pubblicazione: (2005)
• Advanced non-small cell lung cancer in patients aged 45 years or younger: outcomes and prognostic factors
  di: Hsu, Chia-Lin, et al.
  Pubblicazione: (2012)
• Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan
  di: Lin, Shu-Yung, et al.
  Pubblicazione: (2018)
• Association of Programmed Death‐Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase‐Positive Lung Adenocarcinoma Receiving Crizotinib
  di: Yang, Ching‐Yao, et al.
  Pubblicazione: (2020)